Influence of fluorescent probe size and cytochrome b5 on drug-drug interactions in CYP2C9

被引:7
|
作者
Hummel, MA
Tracy, TS
Hutzler, JM
Wahlstrom, JL
Zhou, YH
Rock, DA
机构
[1] Pfizer Inc, Pfizer Global Res & Dev, St Louis Labs, Pharmacokinet Dynam & Metab, St Louis, MO 63017 USA
[2] Univ Minnesota, Dept Expt & Clin Pharmacol, Minneapolis, MN 55455 USA
关键词
CYP2C9; drug interactions; fluorescent; inhibition; cytochrome b5;
D O I
10.1177/1087057105285612
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
7-Methoxy-4-trifluoromethylcoumarin (MFC) has been used extensively in high-throughput screens for the identification of potential CYP2C9 interactions. More recently, additional probes from Invitrogen have been used. Vivid 2C9 Green is the largest of the probes and has had limited prior characterization. The new series of probes differ significantly from MFC and were examined for their ability to identify interactions with 19 CYP2C9 substrates/inhibitors. The inhibition profiles depend largely oil the physical differences between the fluorescent probe substrates. Cytochrome b5 (cytb5) was also investigated for the ability to alter the inhibition profile of a given compound. The stoichometric addition of cyt b5 caused an increase in Vmax of MFC and Vivid 2C9 Green 4.4 and 1.7 times, respectively. Furthermore, cyt b5 imposes a steric component to the active site as the inhibition profiles were significantly affected in incubations with MFC. The addition of cyt b5 had limited impact on the inhibition profiles generated with Vivid 2C9 Green. The K,, of Vivid 2C9 Green increased from 1.2 +/- 0.2 mu M to 4.8 +/- 0.3 mu M as a result of cyt b5 addition. These results illustrate that multiple substrate probes may be necessary for screening drug-drug interaction in CYP2C9 and that cyt b5 effects can impart steric restraints on the CYP2C9 active site.
引用
收藏
页码:303 / 309
页数:7
相关论文
共 50 条
  • [31] Organic Anion Transporter 2 Mediates Hepatic Uptake of Tolbutamide, a CYP2C9 Probe Drug
    Bi, Yi-an
    Mathialagan, Sumathy
    Tylaska, Laurie
    Fu, Myra
    Keefer, Julie
    Vildhede, Anna
    Costales, Chester
    Rodrigues, A. David
    Varma, Manthena V. S.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2018, 364 (03): : 390 - 398
  • [32] EVALUATION OF DRUG-DRUG INTERACTIONS OF RUCAPARIB AND CYP1A2, CYP2C9, CYP2C19, CYP3A4, AND P-GP SUBSTRATES IN PATIENTS WITH ADVANCED SOLID TUMORS.
    Xiao, J. J.
    Nowak, D.
    Ramlau, R.
    Tomaszewska-Kiecana, M.
    Wysocki, P. J.
    Isaacson, J.
    Beltman, J.
    Nash, E.
    Kaczanowski, R.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 : S92 - S93
  • [33] CYP2C19 drug-drug and drug-gene interactions in ED patients
    Flaten, Hanna K.
    Kim, Howard S.
    Campbell, Jenny
    Hamilton, Lisa
    Monte, Andrew A.
    AMERICAN JOURNAL OF EMERGENCY MEDICINE, 2016, 34 (02): : 245 - 249
  • [34] Pharmacokinetic Evaluation of the CYP3A4 and CYP2C9 Drug-Drug Interaction of Avacopan in 2 Open-Label Studies in Healthy Participants
    Miao, Shichang
    Bekker, Pirow
    Armas, Danielle
    Lor, Mary
    Han, Yanyan
    Webster, Kenneth
    Trivedi, Ashit
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2024, 13 (05): : 517 - 533
  • [35] Effect of antituberculosis drug therapy on hepatic drug metabolizing enzyme CYP2C9
    Melvin, G.
    Shewade, D. G.
    Saka, V. K.
    Adithan, C.
    INDIAN JOURNAL OF PHARMACOLOGY, 2008, 40 : 56 - 57
  • [36] Midazolam as a Probe for Heterotropic Drug-Drug Interactions Mediated by CYP3A4
    Denisov, Ilia G.
    Grinkova, Yelena V.
    McLean, Mark A.
    Camp, Tyler
    Sligar, Stephen G.
    BIOMOLECULES, 2022, 12 (06)
  • [37] Catalytic roles of CYP2C9 and its variants (CYP2C9*2 and CYP2C9*3) in lornoxicam 5′-hydroxylation
    Iida, I
    Miyata, A
    Arai, M
    Hirota, M
    Akimoto, M
    Higuchi, S
    Kobayashi, K
    Chiba, K
    DRUG METABOLISM AND DISPOSITION, 2004, 32 (01) : 7 - 9
  • [38] Effect of anti-tuberculosis therapy on polymorphic drug metabolizing enzyme CYP2C9 using phenytoin as a probe drug
    George, Melvin
    Shewade, Deepak Gopal
    Kumar, Saka Vinod
    Adithan, Chandrasekaran
    INDIAN JOURNAL OF PHARMACOLOGY, 2012, 44 (04) : 485 - 488
  • [39] EVALUATION OF CYP2B6 INDUCTION AND PREDICTION OF CLINICAL DRUG-DRUG INTERACTIONS
    Fahmi, Odette A.
    DRUG METABOLISM AND PHARMACOKINETICS, 2017, 32 (01) : S18 - S18
  • [40] Drug-drug interaction of losartan and glimepiride metabolism by recombinant microsome CYP2C9*1, 209*3, 209*13, and 2C9*16 in vitro
    Chen, Sai-Zhen
    Pan, Pei-Pei
    Shen, Lei-Bin
    Xu, Shan-Shan
    Dai, Da-Peng
    Geng, Pei-Wu
    Cai, Jie
    Cai, Jian-Ping
    Hu, Guo-Xin
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2014, 52 (09) : 732 - 738